Narco Scientific, Inc

Text (OCR of the scan at left; may contain errors)

IN THE MATTER OF NARCO SCIENTIFIC, INC.

CONSENT ORDER , ETC., IN REGARD TO ALLEGED VIOLATION OF SEC. 50l' THE FEDERAL TRADE COMMISSION ACT AND SEC. 8 OF THE CLAYTON ACT Docket C-3036'. Complaint, Aug. 21. 1980-Decision, Aug. 21. 1980 This consent order prohibits, among other things, a Fort Washington, Pa. corporation from having as a director any individual who also serves as a director of any competitive company whose revenues exceed the lesser of ten million dollars or one percent of the company s total annual revenues. Appearances For the Commission: Dennis F Johnson and Thomas J Keary. For the respondent: James Rosenberg, Saul, Ewing, Remick & Saul, Philadelphia, Pa.

COMPLAINT The Federal Trade Commission, having reason to believe that the above-named respondents have violated the provisions of Section 8 of the Clayton Act, 15 U. C. 19, and Section 5(a)(I) of the Federal Trade Commission Act, 15 U.s.c. 45(a)(I), and that a proceeding by it in respect thereof would be in the public interest, issues this complaint, stating its charges as follows: COUNT I PARAGRAPH 1. Gould Inc. ("Gould") is a corporation organized under the laws of the State of Delaware, with its principal place of business located at 10 Gould Center, Rollng Meadows, Ilinois. Gould has capital, surplus and undivided profits aggregating more than one milion dollars.

PAR. 2. Respondent Midland-Ross Corporation ("Midland-Ross ) is a corporation organized under the laws of the State of Ohio, with its principal place of business located at 20600 Chagrin Boulevard Cleveland, Ohio. Midland-Ross has capital, surplus and undivided profits aggregating more than one milion dollars. PAR. 3. Respondent Claude M. Blair is an individual, with his principal place of business located at National City Corporation, Post Offce Box 5756, Cleveland, Ohio.

PAR. 4. Gould conducts its business, as described herein, in various l'l.f.fL-V OL-JL1 JI.( , JJ 178 Complaint States of the United States and is thereby engaged in activity in or affecting commerce within the meaning of Section Four of the Federal Trade Commission Act, as amended, 15 U. c. 44, and Section 1 of the Clayton Act, 15 U.s.C. 12. PAR. 5. Midland-Ross conducts its business, as described herein, in various States of the United States and is thereby engaged in activity in or affecting commerce within the meaning of Section Four of the Federal Trade Commission Act, as amended, 15 U.S. c. 44, and Section 1 ofthe Clayton Act, 15 U.s. C. 12. PAR. 6. Claude M. Blair was, until his resignation from Gould' board of directors on or about July 24, 1979, a member of the boards of directors of both Gould and Midland-Ross. He has been a director of Midland-Ross since 1974, and was a director of Gould from 1969 until his resignation.

PAR. 7. During all or part of the period that Claude M. Blair concurrently served as a director of Gould and Midland-Ross, the business of Gould and Midland-Ross included the manufacture and sale of various electrical products, including electrical busways and electrical conduit fittings.

PAR. 8. By the nature of their business as hereinabove described and the locations of their operations, Gould and Midland-Ross have been competitors, during all or part of the time period that Claude M. Blair concurrently served as a director of Gould and Midland- Ross, so that the elimination of competition by agreement between them would constitute a violation of the antitrust laws. PAR. 9. The simultaneous membership of Claude M. Blair on the boards of directors of Gould and Midland-Ross constitutes a violation of Section 8 of the Clayton Act and Section 5(a)(I) of the Federal Trade Commission Act.

COUNT II PAR. 10. Paragraphs One and Four are incorporated herein. PAR. 11. Respondent Narco Scientific, Inc. ("Narco ) is a corporation organized under the laws of the State of Delaware, with its principal place of business located at Fort Washington Industrial Park, Fort Washington, Pennsylvania. Narco has capital, surplus and undivided profits aggregating more than one millon dollars. PAR. 12. Respondent William C. Musham is an individual, with his principal place of business located at Gould Inc., 10 Gould Center Rolling Meadows, l1inois.

PAR. 13. Narco conducts its business, as described herein, in various States of the United States and is thereby engaged in activity Decision and Order 96 F. in o affecting commerce within the meaning of Section Four of the Federal Trade Commission Act, as amended, 15 U. C. 44, and Section 1 of the Clayton Act, 15 U. C. 12. PAR. 14. Wiliam C. Musham was, until his resignation from Narco s board of directors during January 1980, a member of the boards of directors of both Gould and N arco. He has been a director of Gould since 1976, and was a director of Narco from 1977 until his resignation.

PAR. 15. During all or part of the period that Wiliam C. Musham concurrently served as a director of Gould and Narco, the business of Gould and Narco included the manufacture and sale of electronic medical devices.

PAR. 16. By the nature of their business as hereinabove described and the locations of their operations, Gould and Narco have been competitors, during all or part of the time period that Wiliam C. Musham concurrently served as a director of Gould and Narco, so that the elimination of competition by agreement between them would constitute a violation of the antitrust laws. PAR. 17. The simultaneous membership of Wiliam C. Musham on the boards of directors of Gould and Narco constitutes a violation of Section 8 of the Clayton Act and Section 5(a)(I) of the Federal Trade Commission Act.

DECISION AND ORDER The Federal Trade Commission, having initiated an investigation of interlocking personnel relationships between Gould Inc. and other corporations, and Narco Scientific, Inc. (hereinafter referred to as Narco ), having been furnished thereafter with a copy of a draft of complaint which the Bureau of Competition proposed to present to the Commission for its consideration and which, if issued by the Commission, would charge Narco with violation of Section 8 of the Clayton Act (15 U. C. 19) and Section 5 of the Federal Trade Commission Act (15 U. C. 45); and Narco, its attorney, and counsel for the Commission having thereafter executed an agreement containing a consent order, an admission by N arco of all the jurisdictional facts set forth in the aforesaid draft of complaint, a statement that the signing of said agreement is for settlement purposes only and does not constitute an admission by Narco that the law has been violated as alleged in such complaint, and waivers and other provisions as required by the Commission s Rules; and The Commission having thereafter considered the matter and 178 Decision and Order having determined that it had reason to believe that Narco has violated the said Acts, and that complaint should issue stating its charges in that respect, and having thereupon accepted the executed consent agreement and placed such agreement on the public record for a period of sixty (60) days, now in further conformity with the procedure prescribed in Section 2.34 of its Rules, the Commission hereby issues its complaint, makes the following jurisdictional findings and enters the following order:

1. N arco is a corporation organized existing and doing business under and by virtue of the laws of the State of Delaware, with its offce and principal place of business located at Fort Washington Industrial Park, Fort Washington, Pennsylvania. 2. The Federal Trade Commission has jurisdiction of the subject matter of this proceeding and of Narco, and the proceeding is in the public interest.

ORDER It is ordered That the following definitions shall apply herein: (a) "Subsidiary" of a corporation means any corporation, partnership, firm, association or other legal or business entity of which 50 percent or more of the issued and outstanding voting securities (or other indicia of control for non-stock business organizations) is owned or controlled, directly or indirectly, by such corporation. (b) "Parent" means any corporation which owns or controls 50 percent or more of the issued and outstanding voting securities (or other indicia of control for non-stock business organizations) of any other business organization.

(c) "Sister" corporations mean corporations that share a common parent.

(d) "Product or service market" means any line of commerce in which Narco s (including its subsidiaries and divisions) annual revenues exceed the lesser of:

(1) Five milion dollars; or (2) One-half of one percent of Narco s total annual revenues. It is further ordered, That Narco, its subsidiaries, successors and assigns, shall forthwith cease and desist from having, and in the future shall not have, any director who also serves as a director of Decision and Order 96 F. any other corporation if N arco and such other corporation are, by virtue of their business and location of operation, competitors, so that the elimination of competition between them would constitute a violation of any of the antitrust laws, providing that the revenues of either corporation derived from the product or service market(s) in which they are competitors exceed the lesser of: (a) Ten milion dollars; or (b) One percent of the total sales of that corporation. It is further ordered, That within thirty (30) days of the date of service of this order, and annually thereafter, Narco shall obtain review, and retain from and as to each of its directors, the name and address of each other corporation not related to Narco as parent, sister or subsidiary, which such director also serves as a director, and a descriptive listing of all products and services manufactured, produced, sold or leased by each such other corporation. N arco shall not permit any person to serve as a director who fails to submit to N arco any information required by this paragraph. N arco shall provide the information received pursuant to this paragraph to the Commission upon request. If competition arises in any product service market between N arco and any other corporation with which N arco shares a common director, by virtue of action taken by such other corporation subsequent to a submission of information by such director pursuant to this paragraph, then Narco shall not be liable under Paragraph II unti the date for the next submission of information.

It is further ordered That within ten (10) days from the date of issuance of this order Narco shall distribute a copy of this order to each of its current directors, and thereafter, shall distribute a copy of this order to each prospective or newly-elected or appointed director. It is further ordered, That Narco shall: (a) within sixty (60) days after the date of service of this order, fie with the Commission a written report setting forth in detail the manner and form in which it has complied with this order; and NARCO SCIENTIFIC, INC. 183 178 Decision and Order (b) fie with the Commission such other reports of compliance as may be requested by the Commission.

It is further ordered That the obligations imposed upon Narco under the terms of this order shall continue for a period of seven years following the date of service of this order. VII It is further ordered, That Narco shan notify the Commission not more than thirty (30) days after any change in the corporation such as dissolution, assignment, or sale resulting in the emergence of a successor corporation, the creation or dissolution of subsidiaries, or any other change in the corporation which may affect compliance obligations arising out of this order.

Complaint 96 F.